HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Vlad, S. C. Articles by Felson, D. T. PubMed PubMed Citation Articles by Vlad, S. C. Articles by Felson, D. T. Related Collections Alzheimer's disease Case control studies Incidence studies

Protective effects of NSAIDs on the development of Alzheimer disease

From the Clinical Epidemiology Research and Training Unit (S.C.V., D.T.F.), Arthritis Center (S.C.V., D.T.F.), and Departments of Neurology, Pathology, and Psychiatry (N.W.K.), Boston University School of Medicine; Department of Health Services (D.R.M.), Boston University School of Public Health, Boston, MA; and Center for Quality, Outcomes and Economic Research (S.C.V., D.R.M.) and Geriatric Research Education and Clinical Center (N.W.K.), Bedford Veterans Affairs Medical Center, Bedford, MA.

Address correspondence and reprint requests to Dr. Steven C. Vlad, Boston University School of Medicine, Clinical Epidemiology Research and Training Unit, 650 Albany St., Suite X200, Boston, MA 02118 svlad{at}bu.edu

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer disease (AD), but observational studies and trials have offered contradictory results. Prior studies have also been relatively short and small. We examined the effects on AD risk of NSAID use for >5 years and of NSAIDs that suppress formation of Aβ_1-42 amyloid in a large health care database.

Methods: Cases were veterans aged 55 years and older with incident AD using the US Veterans Affairs Health Care system. Matched controls were drawn from the same population. NSAID exposure was categorized into seven time periods: no use, 1 year, >1 but 2 years, and so on. Using conditional logistic regression, adjusted for race and comorbidities, we tested the association between AD development and the use of 1) any NSAID, 2) any NSAID excluding nonacetylated salicylates, 3) each NSAID class, 4) each individual NSAID, and 5) Aβ_1-42-suppressing NSAIDs.

Results: We identified 49,349 cases and 196,850 controls. Compared with no NSAID use, the adjusted odds ratios for AD among NSAID users decreased from 0.98 for 1 year of use (95% CI 0.95–1.00) to 0.76 for >5 years of use (0.68–0.85). For users of ibuprofen, it decreased from 1.03 (1.00–1.06) to 0.56 (0.42–0.75). Effects of other NSAID classes and individual NSAIDs were inconsistent. There was no difference between a group of Aβ_1-42-suppressing NSAIDs and others.

Discussion: Long-term nonsteroidal anti-inflammatory drug (NSAID) use was protective against Alzheimer disease. Findings were clearest for ibuprofen. Aβ_1-42-suppressing NSAIDs did not differ from others.

Abbreviations: AD = Alzheimer disease; ADAPT = Alzheimer’s Disease Anti-inflammatory Prevention Trial; COX-2 = cyclooxygenase-2; DEpiC = Disease Epidemiology Cohorts; NSAID = nonsteroidal anti-inflammatory drug; VA = Veterans Affairs.

Supplemental data at www.neurology.org

Supported by NIH grants AR47785 and AR07598.

Disclosure: The authors report no conflicts of interest.

Received September 18, 2007. Accepted in final form January 14, 2008.

This article has been cited by other articles:

				Continued Support for Protective Effects of NSAIDs in Alzheimer Disease Journal Watch Neurology, September 2, 2008; 2008(902): 2 - 2. [Full Text]